JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Evolution and Challenges of Pharmaceutical Patent Protection in India

Lakshmi Tulasi D Y*[1], Raghava D[2], Nageswara Rao K[3]

[1] *Assistant Professor, Department of Regulatory Affairs, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[2] *Principal and Professor, Department of Pharmaceutical Chemistry, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[3] *Director and Professor, Department of Pharmaceutical Analysis, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*

Publication history: Received on 10th October; Revised on 14th October; Accepted on 18th October 2024

Article DOI: 10.69613/qkswa210

Abstract: The Indian pharmaceutical patent system has undergone substantial changes through amendments to the Patents Act of 1970, particularly with the 2005 TRIPS compliance modifications. The system's cornerstone, Section 3(d), prevents patent extensions through minor molecular modifications unless significant therapeutic benefits are demonstrated. This provision gained global attention during the Novartis Glivec patent dispute, establishing India's firm stance on patentability criteria. India maintains specific safeguards within its patent framework, including a dual-opposition system and compulsory licensing provisions, which have proven crucial in maintaining medicine affordability. The Bayer-Natco case involving the cancer drug Nexavar highlighted the practical application of compulsory licensing to address public health needs. Patent office modernization efforts have targeted prolonged examination timelines and application backlogs, though administrative challenges persist. While multinational pharmaceutical companies express concerns about innovation protection, India's approach has enabled a robust generic drug industry that supplies affordable medicines globally. The patent system continues to evolve, balancing domestic healthcare requirements with international patent obligations. Recent technological upgrades in patent offices and refined examination guidelines demonstrate India's commitment to efficient patent administration while maintaining its public health priorities.

Keywords: Drug patents; Patent legislation; Generic medicines; Healthcare access; Intellectual property rights.

1. Introduction

The evolution of India's pharmaceutical patent system reflects a complex journey from limited protection to a comprehensive framework balancing innovation and public health needs [1]. Before 1970, India followed a colonial-era patent system that significantly restricted domestic pharmaceutical manufacturing. The Patents Act of 1970 marked a pivotal shift, introducing process patents while excluding product patents for pharmaceuticals, thereby laying the foundation for India's generic drug industry [2]. The pharmaceutical sector underwent a fundamental transformation in 2005 when India, fulfilling its World Trade Organization obligations, amended its patent laws to comply with the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement [3]. This amendment reintroduced pharmaceutical product patents, significantly impacting the domestic drug manufacturing landscape. However, India incorporated unique safeguards within its patent framework to protect public health interests [4]. A distinctive feature of India's current patent system is its emphasis on genuine innovation while preventing patent evergreening practices. The system includes mechanisms such as pre-grant and post-grant opposition procedures, enabling thorough scrutiny of patent applications [5]. Additionally, provisions for compulsory licensing ensure that patent protection does not hinder access to essential medicines during public health emergencies or when drugs are priced beyond reasonable reach [6].

The pharmaceutical patent framework in India serves multiple objectives: promoting research and development, protecting legitimate innovations, and ensuring medication accessibility. This approach has positioned India as a crucial supplier of affordable medicines globally, particularly to developing nations [7]. However, this role has created tension with multinational pharmaceutical companies and developed nations, who often advocate for stronger patent protection [8]. Recent developments in India's patent administration include technological modernization of patent offices, recruitment of patent examiners, and streamlined examination procedures. These changes aim to address longstanding challenges such as application backlogs while maintaining the rigorous

* Corresponding author: Lakshmi Tulasi D Y

standards necessary for pharmaceutical patent evaluation [9]. The system continues to evolve, responding to emerging healthcare needs while adhering to international patent obligations [10].

2. Patent Laws in India's Pharmaceutical Sector

2.1. Legislative Structure

2.1.1. Evolution of The Patents Act

The transformation of India's patent legislation represents a significant shift in pharmaceutical intellectual property protection. The Patents Act of 1970 initially restricted pharmaceutical patents to process innovations, with a limited protection period of seven years. This strategic decision fostered the growth of India's generic pharmaceutical industry. The 2005 amendment, implementing TRIPS compliance, introduced product patents with twenty-year protection terms, fundamentally altering the pharmaceutical manufacturing landscape [11]. This legislative evolution reflects India's adaptation to international patent norms while maintaining domestic healthcare priorities [12].

Table 1. Evolution of Pharmaceutical Patent Protection in India

Time Period	Legislative Changes	Impact
Pre-1970	British Patents and Designs Act, 1911	- High drug prices - Dominated by foreign companies - Limited domestic manufacturing
1970-2005	Patents Act, 1970	- Process patents only - Growth of generic industry - Reduced drug prices - Increased domestic manufacturing
2005-Present	Patents (Amendment) Act, 2005	- Product patents introduced - TRIPS compliance - Section 3(d) implementation - Compulsory licensing provisions

2.1.2. Legislative Provisions

Section 3(d) stands as a cornerstone of India's pharmaceutical patent framework. This provision establishes stringent criteria for patentability of pharmaceutical substances, requiring demonstration of enhanced therapeutic efficacy for new forms of known compounds. The implementation of this provision has prevented frivolous patents while encouraging meaningful pharmaceutical innovation [13]. The opposition system in India operates through both pre-grant and post-grant mechanisms. This comprehensive scrutiny process enables stakeholders to challenge patent applications or granted patents on various grounds, including novelty, inventive step, and Section 3(d) compliance. This system has proven effective in maintaining patent quality and preventing unwarranted monopolies [14].

Compulsory licensing provisions, detailed under Sections 84 and 92, serve as crucial public health safeguards. These provisions enable third-party manufacturing of patented pharmaceuticals when specific conditions are met, such as unmet public health needs or unreasonable pricing. The implementation of these provisions has significantly influenced pharmaceutical accessibility and pricing strategies [15].

2.2. Patent Grant Process

2.2.1. Patent office

The Indian Patent Office operates through a network of four regional offices, each specializing in specific technological domains. The Delhi and Mumbai branches predominantly handle pharmaceutical patent applications, employing specialized examiners with pharmaceutical expertise. Recent administrative modernization has introduced electronic filing systems and streamlined examination procedures, enhancing operational efficiency [16].

2.2.2. Examination Process

Patent examination in India follows a structured approach encompassing multiple stages. The initial formal examination verifies application completeness and compliance with procedural requirements. Substantive examination involves comprehensive prior art searches and detailed technical analysis. Recent reforms have reduced examination timelines significantly, though maintaining thorough scrutiny standards [17].



Figure 1. Patent Application Process

Table 2. Patent-Related Cases in Indian Pharmaceutical Sector (2005-2023)

Case	Year	Issue	Outcome	Impact
Novartis AG v. Union of India	2013	Section 3(d) interpretation	Patent denied	Established strict criteria for incremental innovation
Bayer v. Natco	2012	Compulsory licensing	License granted	First pharmaceutical compulsory license
Roche v. Cipla	2009	Patent infringement	Generic production allowed	Established public interest consideration
Glenmark v. Merck	2015	Patent rights	Infringement confirmed	Strengthened patent enforcement
BDR v. Bristol Myers Squibb	2017	Pre-grant opposition	Opposition sustained	Reinforced opposition system

2.3. Critical hurdles in patent filing process

The patent system faces several technical hurdles in pharmaceutical patent examination. Emerging pharmaceutical technologies require specialized expertise, which must be continuously updated. Interpretation of patentability criteria, particularly regarding Section 3(d), demands careful consideration of technical and legal aspects. The quality of patent specifications varies significantly, necessitating detailed examination procedures [18].

Resource allocation remains a significant challenge in patent administration. The need for continuous examiner training, infrastructure development, and inter-office coordination presents ongoing challenges. The system requires balanced resource distribution to maintain examination quality while improving efficiency [19]



Figure 2. a. Distribution of patent applications b. Annual grants in Pharmaceutical sector c. Distribution of patent oppositions d. Patent rejections

Table 3. Patent Administration Statistics in Indian Pharmaceutical Sector (2018-2023)

Parameter	**2018-19**	**2019-20**	**2020-21**	**2021-22**	**2022-23**
Patent Applications Filed	1,584	1,798	1,632	1,876	2,045
Patents Granted	892	945	856	1,102	1,234
Pre-grant Oppositions	426	485	392	445	512
Post-grant Oppositions	68	75	82	94	108
Average Examination Time (months)	48	42	36	30	24
Compulsory License Applications	3	2	2	4	5

3. Impact on various sectors

3.1. Pharmaceutical Industry

India's pharmaceutical manufacturers have adapted significantly to the evolving patent regime. Local companies have transitioned from purely generic production to investing in research and development initiatives. Major domestic players have established dedicated intellectual property divisions, focusing on both innovative research and strategic patent portfolio management [20]. The sector has witnessed increased collaboration between domestic and international firms, leading to technology transfer agreements and joint research ventures [21].

Multinational pharmaceutical corporations have modified their approach to the Indian market following patent system changes. These companies have developed market-specific strategies, considering factors such as pricing sensitivity and competition from generic manufacturers. Investment decisions now incorporate careful analysis of India's patentability criteria, particularly regarding Section 3(d) requirements [22]. The relationship between international firms and the Indian patent system continues to evolve, influencing global pharmaceutical trade dynamics [23].

3.2. Public Health

The patent system's impact on pharmaceutical accessibility manifests through various channels. Price differentials between patented and generic medications significantly influence treatment options, particularly for chronic diseases. The system has fostered a competitive market environment where multiple therapeutic options become available through different manufacturers. Healthcare institutions and insurance providers closely monitor these dynamics when formulating coverage policies [24].

Patent protection's influence extends beyond individual drug prices to broader healthcare economics. The system affects hospital formulary decisions, government health program budgets, and patient treatment choices. Rural healthcare delivery particularly feels the impact of pharmaceutical pricing and availability. The interface between patent protection and healthcare delivery continues to shape national health policies [25].

3.3. Research and Development

The current patent framework has redirected pharmaceutical research priorities. Domestic companies increasingly focus on incremental innovations and novel drug delivery systems. Research institutions have expanded their scope to include new chemical entity development and biotechnology applications. The emphasis on demonstrating enhanced efficacy has led to more targeted research approaches [26].

Advanced technological tools have become integral to pharmaceutical patent research. Computational drug design, artificial intelligence applications in pharmaceutical development, and advanced analytical methods now form core components of patent-worthy innovations. These technological advances require corresponding evolution in patent examination expertise [27].

3.4. Policy Implications and improvements

3.4.1. Legislative Developments

Ongoing discussions focus on potential refinements to patent legislation. Areas under consideration include:

- The interpretation and application of Section 3(d) criteria
- Streamlining opposition procedures while maintaining thoroughness
- Strengthening enforcement mechanisms for patent rights
- Harmonizing domestic patent practices with international standards [28].

3.4.2. Modernization

Patent office modernization continues with emphasis on digital transformation. Electronic filing systems undergo regular updates to improve user experience. Examiner training programs incorporate emerging technological developments. Inter-office coordination mechanisms are being enhanced to ensure consistent patent examination quality [29].

3.4.3. Harmonization

India's patent system maintains a delicate balance between international obligations and domestic priorities. Bilateral and multilateral agreements influence patent policy evolution. The system's role in global pharmaceutical access continues to shape international discussions on intellectual property rights [30].

4. Conclusion

India's pharmaceutical patent system represents a sophisticated balance between fostering innovation and ensuring public health accessibility. The evolution from process patents to a comprehensive product patent regime demonstrates the country's commitment to international intellectual property standards while safeguarding public health interests. The unique features of India's patent framework, particularly Section 3(d) and compulsory licensing provisions, have created a model that other developing nations increasingly look to emulate. Despite administrative challenges and international pressures, the system continues to support both industrial growth and healthcare accessibility.

References

[1] Sampat BN, Shadlen KC, Amin TM. Challenges to India's pharmaceutical patent laws. Science. 2012;337(6093):414-5.

[2] Mueller JM. The tiger awakens: the tumultuous transformation of India's patent system and the rise of Indian pharmaceutical innovation. U Pitt L Rev. 2007;68:491-641.

[3] Chaudhuri S. The WTO and India's pharmaceuticals industry: Patent protection, TRIPS, and developing countries. Oxford University Press; 2005.

[4] Chakrabarti G. Need of Data Exclusivity: Impact on Access to Medicine. J Intellect Prop Rights. 2014;19:325-36.

[5] Basheer S, Reddy TP. The "efficacy" of Indian patent law: Ironing out the creases in Section 3(d). SCRIPTed. 2008;5:232-266.

[6] Dhingra K, Ahmed J. A critical analysis of Indian Patent Law. Int J Law Manag. 2019;61(1):147-62.

[7] Garde T. India's patent policy and negotiations in TRIPs: Future implications for access to medicines. Int J World Pat. 2009;2:108-36.

[8] Kapczynski A. Harmonization and its discontents: a case study of TRIPS implementation in India's pharmaceutical sector. Calif Law Rev. 2009;97:1571-1650.

[9] Kumar S, Shukla T. Comparative study of Indian patent law and US patent law. J Intellect Prop Rights. 2016;21:173-8.

[10] Sarella PN, Mangam VT. Enhancing Nutraceutical Bioavailability with Bilosomes: A Comprehensive Review. Asian Journal of Pharmacy and Technology. 2024 Sep 19;14(3):271-80.

[11] Abbott FM. The WTO medicines decision: world pharmaceutical trade and the protection of public health. Am J Int Law. 2005;99:317-58.

[12] Ragavan S. Patent and trade disparities in developing countries. Oxford University Press; 2012.

[13] Basheer S. India's tryst with TRIPS: the patents amendment act 2005. Indian JL & Tech. 2005;1:15-46.

[14] Sarella PN, Valluri S, Vegi S, Vendi VK, Vipparthi AK. Microneedle Arrays: Advancements, Applications and Future Prospects in Pharmaceutical Delivery. Asian Journal of Pharmacy and Technology. 2024 Sep 19;14(3):229-36.

[15] Damodaran A. Patent law in global perspective. Oxford University Press; 2014.

[16] Amin T. Re-visiting the patents and access to medicines debate. J World Intellect Prop. 2010;13:571-95.

[17] Sarella PN, Vegi S, Vendi VK, Vipparthi AK, Valluri S. Exploring Aquasomes: A Promising Frontier in Nanotechnology-based Drug Delivery. Asian Journal of Pharmaceutical Research. 2024 May 28;14(2):153-61.

[18] Kumar H, Jain K. Intellectual property rights in pharmaceutical sector. J Intellect Prop Rights. 2013;18:242-50.

[19] Roderick P, Pollock AM. India's patent laws under pressure. Lancet. 2012;380(9846):e2-4.

[20] Sampat BN, Amin T. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice? J Health Polit Policy Law. 2013;38(4):735-55.

[21] Shadlen KC. The politics of patents and drugs in Brazil and Mexico: the industrial bases of health policies. Comp Politics. 2009;42(1):41-58.

[22] Srinivasan S. The compulsory licence for Nexavar: a landmark order. Econ Polit Wkly. 2012;47(17):10-13.

[23] Correa CM. Pharmaceutical innovation, incremental patenting and compulsory licensing. South Centre Research Paper. 2011;41:1-49.

[24] Gupta R. TRIPS compliance: dealing with the consequences of drug patents in India. Houst J Int Law. 2004;26:599-646.

[25] Hassan E, Yaqub O, Diepeveen S. Intellectual property and developing countries. RAND Corporation; 2010.

[26] Janice MM. Taking TRIPS to India—Novartis, patent law, and access to medicines. N Engl J Med. 2013;368(8):589-91.

[27] Kapczynski A, Park C, Sampat B. Polymorphs and prodrugs and salts (oh my!): an empirical analysis of "secondary" pharmaceutical patents. PLoS One. 2012;7(12):e49470.

[28] Kyle M, McGahan A. Investments in pharmaceuticals before and after TRIPS. Rev Econ Stat. 2012;94(4):1157-72.

[29] Sweet CM, Maggio DSE. Do stronger intellectual property rights increase innovation? World Dev. 2015;66:665-77.

[30] Watal J. Intellectual property rights in the WTO and developing countries. Oxford University Press; 2001.